Regulation of transforming growth factor-β signaling as a therapeutic approach to treating colorectal cancer

doi:10.3748/wjg.v28.i33.4744

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 28, Issue 33

This Article

(226)

(230)

(0)

(11)

(1)

(8495)

(17)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Gastroenterol. Sep 7, 2022; 28(33): 4744-4761
Published online Sep 7, 2022. doi: 10.3748/wjg.v28.i33.4744

Table 3 Clinical trials of drugs for the treatment of colorectal cancer (United States National Library of Medicine; ClinicalTrials.gov)

Clinical trials (phase)	Drug	Target	Mechanism of action
Antisense oligonucleotides
NCT00844064 (I)	AP12009 (trabedersen)	TGF-β2	By binding to TGF-βII mrna, its expression is reduced
Antibodies
NCT04952753 (II)	NIS793	TGF-β	Reduction of active cytokine, reduction of SMAD2/3 phosphorylation, and reduction of TGF-β target gene expression
NCT02947165 (I)	NIS793	TGF-β	Reduction of active cytokine, reduction of SMAD2/3 phosphorylation, and reduction of TGF-β target gene expression
NCT01646203(I)	IMC-TR1	TGF-βRII	Reduction of active cytokine, reduction of SMAD2/3 phosphorylation, and reduction of TGF-β target gene expression
Ligand traps
NCT03436563 (I/II)	M7824	TGF-βRII	Bifunctional anti-PD-L1/TGF-βRII trap fusion protein
NCT02517398(I)	Bintrafusp alfa	TGF-βRII and PD-L1	First-in-class bifunctional fusion protein composed of a mab against PD-L1 fused to the extracellular domain of the TGF-β receptor II
NCT04856787 (II/III)	SHR-1701	TGF-βRII	Bifunctional anti-PD-L1/TGF-βRII agent
Small molecule receptor kinase inhibitors
NCT04031872 (I/II)	LY3200882; capecitabine	TGF-βRI	By blocking ATP binding to TGF-βR, receptor kinase activity and signal transduction are reduced
NCT05400122 (I)	Vactosertib	TGF-βRI	Inhibits the activity of TGF-βR1
NCT03724851 (I/II)	Vactosertib + Pembroli-zumab	TGF-βRI	Inhibits the activity of TGF-βR1
NCT03470350 (I/II)	Galunisertib	TGF-βRI	Inhibits the activity of TGF-βR1
Immune checkpoints
NCT04540159		TGF-β1	Measuring the level Active TGF-β1 by flow-cytometric analysis in the intraabdominal ascites
Adoptive cell therapy
NCT03431311 (I/II)	ACT	TGF-βII	ACT with Radium-1 TCR + T cells transiently redirected against the TGF-βRII frameshift antigen which is expressed in MSI+ colon cancer.
NCT05040568 (I)	CB-NK-TGF-Î²R2-/NR3C1		Immunotherapy with ex vivo preactivated and expanded CB-NK cells in combination with cetuximab

ACT: Adoptive cell therapy; TGF: Transforming growth factor.

Full Size Table

Citation: Maslankova J, Vecurkovska I, Rabajdova M, Katuchova J, Kicka M, Gayova M, Katuch V. Regulation of transforming growth factor-β signaling as a therapeutic approach to treating colorectal cancer. World J Gastroenterol 2022; 28(33): 4744-4761
URL: https://www.wjgnet.com/1007-9327/full/v28/i33/4744.htm
DOI: https://dx.doi.org/10.3748/wjg.v28.i33.4744

Maslankova J, Vecurkovska I, Rabajdova M, Katuchova J, Kicka M, Gayova M, Katuch V. Regulation of transforming growth factor-β signaling as a therapeutic approach to treating colorectal cancer. World J Gastroenterol 2022; 28(33): 4744-4761 [PMID: 36156927 DOI: 10.3748/wjg.v28.i33.4744]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.